Cities and counties have been at the forefront of litigation against opioid makers, seeking to hold pharma companies accountable for their spending on the addiction epidemic. Now the feds are getting involved. More: Justice Department steps in to back hundreds
read moreNovo Nordisk has filed regulatory applications in the US and European Union seeking approval to market N8-GP for the treatment of haemophilia More: Novo files N8-GP in the US and EU Source: News
read moreGW Pharma’s cannabidiol (CBD) has been granted orphan drug designation by European regulators for the treatment of tuberous sclerosis (TS). More: GW’s cannabidiol gets EU orphan status for TS Source: News
read moreEuropean regulators will undertake an accelerated assessment of Shire’s hereditary angioedema (HAE) drug lanadelumab. More: Speedy EU review for Shire’s lanadelumab Source: News
read moreThe European Commission has licensed Roche/Chugai’s Hemlibra for the routine prevention of bleeding episodes in patients with haemophilia A with factor VIII inhibitors. More: Roche/Chugai’s Hemlibra wins green light for bleeding disorder Source: News
read moreAstraZeneca’s biologics research and development arm MedImmune has spun out six molecules from its early-stage inflammation and autoimmunity programmes into new independent biotech Viela Bio. More: AstraZeneca spins out new firm Viela Bio Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals